1,4-二甲基-2-苯基哌嗪 | 5271-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1,4-二甲基-2-苯基哌嗪
• 英文名称: 1,4-dimethyl-2-phenylpiperazine
• CAS: 5271-29-4
• 化学式: C₁₂H₁₈N₂
• 分子量: 190.288
• InChiKey: WPJRBEGBIRXHNW-UHFFFAOYSA-N

物化性质

• 沸点：
  88 °C(Press: 0.5 Torr)
• 密度：
  0.987±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯基丙醇水合物 、 N,N'-二甲基乙二胺 在 glucose-6-phosphate dehydrogenase 、 glucose-6-phosphate 、 Myxococcus stipitatus R-selective imine reductase 、 还原型辅酶II(NADPH)四钠盐 、 magnesium chloride 作用下， 以 aq. phosphate buffer 为溶剂， 反应 4.0h， 生成 1,4-二甲基-2-苯基哌嗪
  参考文献：
  名称：

  从二胺和二羰基生物催化获得哌嗪

  摘要：

  考虑到哌嗪作为生产药物的基础材料的广泛重要性，非常需要有效和选择性的合成。在这里，我们显示了使用来自粘球菌的R-选择性亚胺还原酶作为生物催化剂，从1,2-二羰基和1,2-二胺底物直接合成哌嗪的方法。在温和的反应条件下获得了高达每升8.1克的各种具有高活性和优异对映选择性的N和C取代的哌嗪。

  DOI：

  10.1021/acscatal.8b00291

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：MEDICAL RES COUNCIL TECHNOLOGY

  公开号：WO2010106333A1

  公开（公告）日：2010-09-23

  A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein R1 is selected from: aryl; heteroaryl; -NHR3; fused aryl-C4-7-heterocycloalkyI; -CONR4R5; -NHCOR6; -C3-7-cycloalkyl; -O-C3-7-cycloalkyl; -NR3R6; and optionally substituted -C1-6 alkyl; wherein said aryl, heteroaryl, fused aryl-C4-7-heterocycloalkyl and C4-7-heterocycloalkyl are each optionally substituted; R2 is selected from hydrogen, aryl, C1-6-alkyl, C2-6-alkenyl, C3-7-cycloalkyl, heteroaryl, C4-7 heterocycloalkyl and halogen, wherein said C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl and C4-7-heterocycloalkyl are each optionally substituted. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (I).

  一种具有式（I）的化合物，或其药学上可接受的盐或酯，其中R1选自：芳基；杂环芳基；-NHR3；融合芳基-C4-7-杂环烷基；-CONR4R5；-NHCOR6；-C3-7-环烷基；-O-C3-7-环烷基；-NR3R6；和可选择地取代的-C1-6烷基；其中所述的芳基、杂环芳基、融合芳基-C4-7-杂环烷基和C4-7-杂环烷基均可选择地取代；R2选自氢、芳基、C1-6-烷基、C2-6-烯基、C3-7-环烷基、杂环芳基、C4-7-杂环烷基和卤素，其中所述的C1-6-烷基、C2-6-烯基、芳基、杂环芳基和C4-7-杂环烷基均可选择地取代。进一步涉及制备具有式（I）的化合物的药物组合物、治疗用途和制备方法的其他方面。
• [EN] 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES<br/>[FR] COMPOSÉS 6-HÉTÉROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE UTILISÉS POUR LE TRAITEMENT DU CANCER ET DU DIABÈTE
  申请人：SPRINT BIOSCIENCE AB

  公开号：WO2017140843A1

  公开（公告）日：2017-08-24

  The invention provides novel 6-heterocyclyl-4-morpholin-4-yl-pyridine-2-one compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and A are as defined in the specification.

  该发明提供了公式（I）的新型6-杂环基-4-吗啡啉-4-基吡啶-2-酮化合物，包含该化合物的药物组合物，以及使用该化合物治疗癌症、糖尿病、炎症性疾病、神经退行性疾病、心血管疾病和病毒感染等疾病的方法；其中R1、R2、R3和A如规范中所定义。
• [EN] CYANOPYRIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS DE CYANOPYRIDINE UTILISÉS EN TANT QU'AGONISTES DES RÉCEPTEURS BÊTA X DU FOIE, COMPOSITIONS ASSOCIÉES ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2017083216A1

  公开（公告）日：2017-05-18

  In its many embodiments, the present invention provides substituted cyanopyridine containing compounds of the Formula (I): and acceptable salts thereof, wherein R1, R2, R3, R4, R5, X, Y, Q, and the moiety are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  在其多种实施方式中，本发明提供了含有化合物的替代氰基吡啶的化合物，其化学式为（I）：及其可接受的盐，其中R1、R2、R3、R4、R5、X、Y、Q和基团如本文所定义。本发明的新化合物以及包含其化合物的药学上可接受的组合物可用作肝X-β受体（LXRβ）激动剂，并且可能用于治疗或预防与之相关的病理。这些病理包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，如阿尔茨海默病。
• Novel method for the preparation of piperazine and its derivatives
  申请人：——

  公开号：US20020095038A1

  公开（公告）日：2002-07-18

  A novel method for the synthesis of piperazine and its derivatives of formula 1, 1 wherein R is selected from hydrogen, or a lower alkyl group having 1 to 6 carbon atoms or a phenylalkyl group the alkyl of which has 1 to 4 carbon atoms; R 1 is selected from hydrogen, a methyl group, a phenyl group optionally substituted with an alkyl group having 1 to 6 carbon atoms, or a phenylalkyl group the alkyl of which has 1 to 4 carbon atoms; and R 2 is selected from hydrogen, or a methyl group, or a fluoromethyl group; 2 comprising the steps: a. reacting an ester of formula 11 with substituted or unsubstituted ethylenediamine of formula 7 to give 3,4-dehydropiperazine-2-one and its derivatives of formula 12, wherein R, R 1 , R 2 are as defined above and R 6 is a C 1 to C 4 linear or branched alkyl group; and b. reacting the 3,4-dehydro-piperazine-2-one and its derivatives of formula 12 with a reducing agent to yield the piperazine and its derivatives of formula 1.

  一种合成1,1-哌嗪及其衍生物的新方法，其中R选择氢，或者具有1至6个碳原子的低级烷基基团或苯基烷基基团，其烷基具有1至4个碳原子; R1选择氢、甲基、苯基（可选地带有1至6个碳原子的烷基基团）或苯基烷基基团，其烷基具有1至4个碳原子; R2选择氢、甲基或氟甲基; 2包括以下步骤：a. 反应式11的酯与式7的取代或未取代的乙二胺反应，得到式12的3,4-去氢哌嗪-2-酮及其衍生物，其中R，R1，R2如上所定义，R6为C1至C4线性或支链烷基基团; b. 反应式12的3,4-去氢哌嗪-2-酮及其衍生物与还原剂反应，得到式1的哌嗪及其衍生物。
• Process for preparing 1-methyl-3-phenylpiperazine using a novel intermediate
  申请人：——

  公开号：US20040242879A1

  公开（公告）日：2004-12-02

  The present invention describes an industrially advantageous process to prepare highly pure 1-Methyl-3-phenylpiperazine of Formula I 1 that makes use of a novel piperazine derivative, 4-Benzyl-1-methyl-2-oxo-3-phenylpiperazine, represented by Formula II 2 1-Methyl-3-phenylpiperazine is a useful intermediate in the preparation of antidepressant Mirtazapine.

  本发明描述了一种工业上有利的工艺，用于制备高纯度的公式I1的1-甲基-3-苯基哌嗪，该工艺利用了一种新型哌嗪衍生物，4-苄基-1-甲基-2-氧代-3-苯基哌嗪，其化学式为II2。1-甲基-3-苯基哌嗪是抗抑郁药米氮平的制备中有用的中间体。